Good afternoon. Thank you for joining us today to discuss the results for LifeMD's First Quarter ended March 31, 2022. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, Chief Financial Officer of LifeMD. Following management's prepared remarks, we will open the call for a question-and-answer session. I'd like to remind everyone that today's call is being hosted via webcast and the recording will be made available via the link in today's press release which is available in the Investor Relations section of the company's website. Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements which are subject to numerous risks and uncertainties that may cause the company's actual results to differ materially from those projected. These risks and uncertainties are described in the company's 10-K and 10-Q filings and other filings that LifeMD may take with the SEC from time to time. Forward-looking statements made during this call are based on current information available to the company as of today, May 13, 2022. The company assumes no obligation to update or revise any forward-looking statements after today's call, except as required by law. Also, please note that the management will be discussing certain non-GAAP financial measures that the company believes are important in evaluating LifeMD's performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliations thereof can be found in the press release issued earlier today. Finally, I would like to remind everyone that today's call is being recorded and will be available for replay in the Investor Relations section of the company's website. Now, I'd like to turn the call over to LifeMD's CEO, Justin Schreiber. Sir, please go ahead.

Thank you, operator, and good afternoon, everyone. Thank you for joining us today to discuss our first quarter 2022 results. In the first quarter of 2022, LifeMD posted its 13th consecutive quarter of sequential revenue growth and a 14% sequential improvement in bottom line profitability. The first quarter was impacted due to a one-time deferral of approximately $1 million in re-billing revenue to the second quarter following a pharmacy-related technology upgrade and short-term headwinds in the advertising market we've since adapted to. That being said, we still remain on track to deliver on our full-year adjusted EBITDA guidance and our previously guided adjusted EBITDA profitability by the fourth quarter. In the first quarter, we successfully closed two acquisitions, executed the launch of our Virtual Primary Care platform, and continued to improve our telehealth, marketing, and technology infrastructure. Our improvement is reflected in the 13% sequential improvement in average order value versus the fourth quarter of 2021. LifeMD announced our first-ever acquisition, Cleared Technologies, in January of this year. Cleared is a nationwide allergy, asthma, and immunology telehealth platform with both direct-to-consumer and business-to-business capabilities. We're now in the process of integrating Cleared into LifeMD's telehealth platform, which we expect to complete by Q3 of this year. We're extremely excited about this acquisition for two reasons. One, the tremendous whitespace opportunity we see in the allergy and asthma telehealth market. Two, we see Cleared as a vehicle for pharma and other healthcare product company partnerships that leverage LifeMD's present and growing telehealth, marketing, and patient adherence capabilities. In a short period since closing the acquisition, we have announced two B2B partnerships and developed a sizable pipeline of additional companies that we believe we will contract with in the coming quarters. We followed up the Cleared deal with the acquisition of ResumeBuild by our subsidiary WorkSimpli in February of 2022. ResumeBuild is a worldwide leader in the digital resume space, and like WorkSimpli, the unit economics of the business are very strong. The WorkSimpli team is already off to a great start with this new platform and expects to amass over 10,000 subscribers in this segment alone before the end of the second quarter. This acquisition further empowers WorkSimpli's transformation into a multifaceted work and document services platform for consumers and small businesses. As stated before, LifeMD is in the early stages of seeking to divest WorkSimpli, and we believe that WorkSimpli's acquisition of ResumeBuild will be highly accretive to its valuation. Having launched our Virtual Primary Care platform this quarter, moving forward, we believe that it will be an important cross-sale to our growing patient population and a big driver of overall lifetime value. Due to some technology-related delays, our cross-sale capability went live this month but it is still a bit too early to share patient count data. However, we are very excited to have just launched this critical capability. Also, in the first quarter, LifeMD successfully drove improvements in our customer AOV and LTV. Among our many initiatives, we introduced new subscription and cross-sale opportunities across our brands, contributing to LifeMD's 13% sequential increases versus the prior quarter in AOV for prescription products. I believe that the combination of growing strength in our core business, coupled with strategic enhancements and new lines of business this quarter positions LifeMD to achieve record results this year, including adjusted EBITDA profitability by year-end. With that, I will now turn the call over to our CFO, Marc Benathen, who will provide a summary of our financial results.

Thank you, Justin, and good morning, everyone. As Justin mentioned, the first quarter of 2022 was another record revenue quarter, marking our 13th consecutive quarter of revenue growth. In addition to this growth, we remain on track to achieve our previously provided full-year 2022 adjusted EBITDA guidance, including obtaining adjusted EBITDA profitability by the fourth quarter 2022. In conjunction with this, we are revising our full-year revenue guidance to be between $132 million and $138 million but without any impact to our bottom line guidance in order to reflect short-term revenue impact from the first quarter, while we remain laser focused on margin expansion, unit economics, and growing profitability. We have begun the process to divest WorkSimpli, including hiring an M&A adviser, and remain very optimistic about this process. Furthermore, WorkSimpli remains a profitable self-funded business which recently returned to growth and is accretive to our company. This is particularly important as it will enable LifeMD to ensure we are only doing the transaction that is in the best interest of our shareholders. Now turning to the results for the first quarter of 2022. Revenue in the first quarter totaled a record $29 million, up 60% compared to the same quarter a year ago. 91% of the total revenues in the first quarter were generated by recurring subscriptions compared to 88% in the same year-ago period. Telehealth net revenues grew by 70% to $22.6 million, while WorkSimpli net revenues grew by 31% to $6.4 million. WorkSimpli revenues did experience a one-time decline in sequential revenues following some initial challenges related to the integration of the ResumeBuild acquisition and some new product enhancements but rebounded strongly in March 2022 with WorkSimpli adding a monthly record of over 13,000 net new subscribers in the month alone. WorkSimpli is expected to return to sequential growth in the second quarter and on a go-forward basis. Gross profit totaled $23.8 million, an increase of 59% from the same year-ago period. Gross profit as a percentage of revenue was 82% for both the quarter ended March 31, 2022, and 2021. Operating expenses for the first quarter totaled $36.9 million, an increase of $10 million versus the year-ago period. This increase was predominantly driven by a $5.3 million increase in general and administrative expenses, and a $3.3 million increase in selling and marketing expenses versus the year-ago period. Operating expenses as a percentage of revenue improved by 2,400 basis points driven by a 2,700 basis point improvement in selling and marketing expenses as a percentage of revenue versus the year-ago period. Our GAAP net loss attributable to common stockholders for the first quarter totaled $14.1 million or $0.46 per share. This compares to a net loss attributable to common stockholders of $11.6 million or $0.47 per share in the first quarter of 2021. Adjusted EPS is a non-GAAP measure that excludes $4.5 million in noncash stock-based compensation expense, $52,000 in financing transactions expense, $531,000 in depreciation and amortization expense, $168,000 in interest expense, $393,000 in nonrecurring charges, and $776,000 in preferred stock dividends. This figure totaled a loss of $0.25 per share for the first quarter compared to a loss of $0.37 per share in the same year-ago period. Adjusted EPS also improved 14% sequentially versus the prior quarter. Adjusted EBITDA, a non-GAAP measure which excludes noncash stock-based compensation, depreciation and amortization expenses, financing transaction expenses, inventory adjustments, preferred stock dividends, nonrecurring charges, and interest expenses totaled a loss of $7.6 million in the first quarter of 2022. This compares to an adjusted EBITDA loss of $9 million in the same year-ago quarter. Now turning to the balance sheet. Cash flow of $25.1 million as of March 31, 2022, included the impact of $7 million of one-time cash outflows related to the two acquisitions we completed in the first quarter plus related working capital. We continue to believe our balance sheet is sufficient to support LifeMD, Inc. as we scale without the need for additional capital. This wraps up our financial results. I’d now like to turn the call back over to Justin.

Thanks, Marc. In summary, while we faced a challenging macro environment that weighed somewhat on our top line results, we were able to produce our 13th consecutive quarter of sequential growth and a 14% sequential improvement in adjusted EPS. We continue to remain on track to meet or exceed our profitability goals this year, leveraging our consistent growth, industry-leading gross margins, and optimizing our operating expenses. We believe that this formula will drive sustained and growing cash flow profitability in the coming quarters. We remain excited for the year ahead, including our relentless pursuit of our mission to revolutionize the U.S. health care system with digital health care. In closing, I would like to thank our entire team for delivering record performance of LifeMD, our affiliated medical providers for the excellent care provided to their patients, and our shareholders for their continued support as LifeMD changes the face of health care. With that, I would like to open the call for Q&A.

We have a first question from David Larsen with BTIG.

Can you please talk a little bit about the $1 million, I think, that you said pushed from 1Q to 2Q? What exactly was that? And then with the reduced revenue guide for the year, can you give a little more color around that? What is driving it? Is that intentional or not because you’re trying to get more profitable revenue in the door? And how is Nava and also the virtual primary care business ramping relative to expectations?

David, this is Marc. So first, to address the $1 million. During the quarter, we actually did a significant upgrade to the company's pharmacy infrastructure and related technology to handle sort of the next leg of growth over the next several years for the company. In doing so, towards the end of the quarter, it pushed out approximately $1 million of re-billed shipments from the first quarter to the second quarter. We only recognize revenue once the product is shipped. That revenue is not lost, but we're just moving it into the second quarter from the first quarter. So that's what that related to. Regarding the revenue guidance, the revenue guidance adjustment was intentional for a couple of reasons. One, we are very focused on maximizing the LTV of our patients and bringing in the most profitable revenue with a higher return on ad spend and a high return on that investment. We continue to get smarter and smarter by the day as we go through that. So this adjustment largely reflected that. We also continue to believe that there could be some bumpiness in the advertising market that we've been very adept at navigating, but we're not going to go after just chasing bad revenue in some cases when you can refine the revenue guidance a bit but maintain our profitability and possibilities and surprise to the upside on the bottom line. And then on Nava, Nava is actually continuing to scale very well. We've actually seen since the fourth quarter of last year, that business has really continued to pick up. Heading into the fourth quarter of last year, they were onboarding approximately 20, 30 new patients a day. Today, that number is in excess of 100, and we'll probably get to 150-plus new patients a day pretty soon. So I'm more excited about where that business is going and where it should be in another 12 months.

Okay. With Nava, how much revenue do you expect that to add in ‘22? And then what could that grow to in ‘23? And then any thoughts Cleared has any revenue been generated there yet or not? And it’s sort of my understanding that if you were going to have a positive revenue surprise for the year, it would come from this new product launches.

Yes, so on the—this is Marc. On the Nava question, for this year, Nava is going to probably generate a little bit south of $5 million for the year in revenue. A lot of that is because it's a business where there's an initial purchase and then the re-billing takes place over a 60-day period. People are typically on a two-month subscription length. So it takes a little bit of time for that to build up. Next year, I would envision that that business is definitely going to be north of $10 million in annual revenue. Exactly what it is, we haven't set in next year's plan, but it will be north of $10 million. On the Cleared piece, yes, we did generate a couple of hundred thousand of initial revenue in the first quarter. We're still going through the direct-to-consumer integration with their technology but began to generate initial B2B revenue through a couple of agreements that we have in place with pharma partners and expect that revenue to continue to grow nicely throughout the year. But as we’ve stated early on when we did the acquisition, for the year, we expect Cleared to be in the range of about $3 million to $4 million of revenue for the year, EBITDA-neutral to slightly accretive, and then begin to see that jump up pretty significantly next year with the business getting to $10 million plus.

David, this is Justin. I'll just add on the Cleared side that the B2B pipeline continues to grow, both direct partnerships with health care product and pharmaceutical companies. But also, we have some other really promising partnerships in the works with larger health care service companies that really could enable us to go to a lot of their entire portfolio of customers at once. So I think it's important; we're very optimistic about everything Alex is doing. And we still maintain our forecast that we're going to build and really start to show a lot of traction this year on the B2B side of things. Hopefully, we'll have a lot more to talk about on that on our next earnings call.

And when you talk about partnerships with large health care service organizations, have those discussions already occurred? And when you say a large organization, I’m thinking like a national health plan, with well over 10 million lives as membership in the U.S. or large hospital systems in certain cities? Are those the kinds of partnerships you’re talking about?

Neither. One is I would say they are companies that have service offerings. And I just—I don't want to be super specific, but they're just companies that are very respected in the health care world that have a large client base that could benefit from LifeMD's B2C telehealth platform. With two of these groups, in particular, there's mutual interest in moving forward and kind of co-marketing our services to their client base. We're very excited about it. In addition to the large pipeline that Alex and the team have built themselves.

That’s helpful. And then with regards to your customer acquisition costs and cost of online advertising and your G&A costs, I mean, how is CAC trending in the quarter relative to 4Q and your expectations? And then how is it trending in April and May for 2Q and 3Q? Just any color there would be helpful.

Yes, so in the first quarter, CAC were pretty much flat with the prior period, both sequentially as well as year-on-year. The main delta, obviously, is we've heard across the market. There was some tightness in the media market, particularly in the beginning of the quarter and at the end of the quarter. The main delta being that on some of those periods, we made the conscious decision to acquire new patients at a slightly lower daily rate than we would have during some other periods where the market was less tight. But the CAC itself was very much consistent with what it's been before and is also very much controllable by us. As far as Q2, we are seeing some slight, and by slight I mean low to mid-single digit percentage improvement in CAC in the second quarter versus the first quarter. The market hasn't changed much, but we had some learnings in the first quarter with some new test strategies that we undertook that actually have proven to be really successful. I don't want to get into the specifics of those for competitive reasons, but they've proven to be very successful. Third quarter, I mean, it's a little bit hard to predict that far out, but we're confident we're going to continue to be able to navigate the environment as we've done in the past.

So, I think what I heard was that advertising costs were actually up in the quarter, but you were able to keep your CACs relatively flat. Is that right?

Not that the ad costs were up. The ad costs are pretty much flat. It was the number of new patients that we brought on that was slightly down versus the prior quarter. But we were able to do that with about a flat amount of spend, so slightly less efficient.

Okay. And then just the last one for me. The G&A costs looked a little bit high relative to our model. Any thoughts there? And it might be stock comp, stock comp…

Yes. It was stock comp. So stock comp came in for the quarter at about $4.5 million, a little bit under that, which was higher than the models that we have. The reason for that was we actually elected to proactively begin to recognize portions of stock-based compensation associated with certain performance awards that were granted in the past that were geared towards the company attaining $100 million of telehealth revenue this year, as well as obtaining adjusted EBITDA profitability. This year because there is some probability—and we think a very high probability—of those awards being achieved this year, rather than take a lump sum hit in one quarter, we pulled forward and amortized that expense over the expected period between now and when will we are. And that was the main delta. Otherwise, our core cash G&A expenses were in line to slightly better than what was expected.

We have the next question from the line of Mark Wiesenberger with B. Riley Securities.

Wondering if you could talk about any changes in patient cohort behavior, maybe shifting subscription plans or any kind of levers that are being pulled within different cohorts across the brands?

Yes, this is Marc. So as we reported, we actually saw a 13% sequential increase in AOV in this quarter versus the prior quarter. Some of that was due to some additional cross-sales that we introduced, particularly within the Rex brand. And then some of it was due to—we've seen success introducing some longer subscription periods. We've introduced the six months subscription and then very recently, a 12-month subscription. We actually saw from three to six months, approximately an 18% take rate in those people that were offered the opportunity to upgrade and trade off, which we were very pleased with the economics on the six month versus three months, or a pretty decent amount better. Obviously, the payback is pretty much instantaneous on those types of subscriptions. We don’t expect the majority of our subscribers to do that. But we are beginning to see traction with some of those longer subscriptions which gives us a little more flexibility on the advertising side but also means we can recoup that investment that much quicker.

Yes, Marc, this is Justin. I'll just add one other thing. We've implemented a lot of new technology over the last couple of months as well, which has been just totally transformational for the cross-sale rate for offering people, other treatment options, both Rx and OTC, and something. It's a very high point right now in the business and something that we think is going to continue to drive unit economics throughout this year and beyond.

Can you talk about the level of promotional activity in the quarter? And maybe your thoughts on that as you ended the second and third quarter?

There was no promotional activity outside of the norm. As a matter of fact, some of the very low-price promotions that we tested last year, we've actually discontinued because we didn't feel that the retention and long-term value of those patients was high enough for our standards and what we wanted. So, no real additional promotional activity. In fact, we're actually going the other direction. We're not raising our prices. Our prices have been consistent with where they have been in the past, but we've been able to find ways to get people to either buy more trade-off from a subscription standpoint.

Got it. And then kind of logically moving from there. I wonder if you could talk about the dynamics around input costs in the quarter, maybe what trends you’re seeing kind of into the second quarter? And then how can you mitigate that and maybe pass some of that on to the patients, if at all?

Yes. We haven't seen any impacts. The biggest impacts are that we're having, particularly on the over-the-counter stuff where we do take in that inventory. We're having to place purchase orders well in advance of when we normally would and then procure. We're taking the approach of procuring a one-year supply locking in lower rates. It's a little bit more of a cash outflow initially, but it's not a material change. On the prescription side, there's been no impact whatsoever. We think that's evidenced in the fact that when we show record level gross margins this quarter, we're not seeing any impacts related to our COGS at the current moment. It's more around just funding our supply chain more carefully than we have in the past.

Understood. And then just two more from me. First one, you did talk about some marketing and advertising headwinds. Could you talk about those kind of across the respective channels? And then yes, I’ll have one more after that.

Yes. It was a bigger impact that we've seen in our entire business and we're going to continue to be parlaying that forward. Quite frankly, had it not been for some of the challenges in the market, we might not have aggressively tested some of those with the successful results that we had. It's really—it’s been just some rate increases in certain areas. Obviously, since all the countries reopened more, the market has been a little bit challenging, but it's nothing that we haven't been able to navigate. What we, as a company, have a philosophy that we want to achieve a 1.6x to 2x return on that ad spend when backing out the cost in the first year. We're not going to go out and do some marketing investment just for the sake of saying we have the highest revenue growth rate. That's just not our philosophy.

Understood. Appreciate that. And then just the last one. Wondering if you could talk about the level of profitability at WorkSimpli in the quarter, how that’s trended over the last couple of quarters, and then expectations moving forward?

Yes. I want to be careful on that because we're in the middle of a process where we're going to be going to market very shortly. We're having the buyer, so we are in the prep period. What I'll say is that the level of profitability has been trending up. We think by the end of the year, the business could have double-digit EBITDA margins by the fourth quarter of this year. Giving out actual figures, I want to be careful about because we are in the middle of a private process.

We have the next question from the line of David Larsen with BTIG.

Just one more quick follow-up. With the LegalSimpli or software business, it looks like the revenue has been pretty flat for the past four quarters. What’s going on there? I mean it had been growing in 1Q of ‘21, I think it was up over 260% year-over-year. Just any color there would be helpful.

Yes. So a couple of things went on initially in the first quarter. So it started in the third quarter of last year where the flatness started. We initially tested some trial offers there that went back to the original mechanism. Then in the last couple of quarters, we've been making some enhancements from assignments and the marketing strategy, as well as we integrated an acquisition this quarter. What's happened with that is the company has really realized that its roots and how they've always approached marketing is the right way to go and they've continued to refine that a little bit. What I will say is it's returning to growth this quarter, hands-down. April was a phenomenal month for it—they actually achieved record revenue in the month of April. As we mentioned, most of that revenue in March is deferred for the following quarter because we do it down to the day on these subscriptions. They signed up over 13,000 net new subscribers, which is new sign-ups less attrition which was a record month for them. A lot of it was just calling back into what's made the business really successful so far and getting away from deviating from that. Now they're in a position where they have the beginnings of a platform offering with offerings in the digital HR resumes space, signature space, PDF space. There are going to be additional offerings that they'll be adding in the future, which should drive that business even more whether we own it or somebody else owns it in the future. But the growth stuff, we're very cognizant of that's behind us. Returning back to growth and profitability is going to be growing each quarter also there.

Okay. And just lastly, any sense for how much revenue the software business generated in April or what your revenue expectations are for the software business for 2Q?

Yes. For the second quarter, I would expect to see revenue in the range of about $7.5 million to $8 million is probably a reasonable range to expect for the second quarter.

That’s helpful. So that would be up around 20% year-over-year in 2Q?

Yes. At this point, because there was a little bit of flatness, we're looking at it more sequentially but yes, it would be up about 25% sequentially.

There are no other questions. And I would like to turn the call back to Justin Schreiber, CEO, for closing remarks. Over to you, sir.

Thanks, everybody, for participating in our earnings call today. Have a great weekend. Look forward to updating everybody on more positive progress on our call next quarter. Thanks.

Thank you. Ladies and gentlemen, this concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.